{"product_id":"orpathys-savolitinib","title":"Orpathys (Savolitinib)","description":"\u003ch2\u003e\u003cspan id=\"About_Aumolertinib\"\u003e\u003cspan id=\"About_Furmonertinib\"\u003eAbout Savolitinib\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eSavolitinib is an oral, potent, and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumours. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations) or gene amplification.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eSavolitinib sold under the brand name Orpathys . \u003c\/li\u003e\n\u003cli\u003eSavolitinib sold under the brand name 沃瑞沙 in china.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2 id=\"Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer\" class=\"title !m-0 break-words text-dark-grey\" data-sb-field-path=\".title\"\u003e\u003cspan id=\"Approval\"\u003eApproval\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eJune 2021, AstraZeneca and HUTCHMED’s Orpathys (savolitinib) has been granted conditional approval in China to treat patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations who have progressed following prior systemic therapy or are unable to receive chemotherapy.\u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"Dosage\"\u003e\u003cspan id=\"Dosage_and_administration\"\u003eDosage\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\u003ch3\u003eRecommended dose and administration\u003c\/h3\u003e\u003cp\u003eFor patients weighing ≥50 kg, the recommended starting dose is 600 mg, taken orally once daily until disease progression or intolerable toxicity occurs.\u003c\/p\u003e\u003cp\u003eFor patients weighing \u0026lt;50 kg, the recommended starting dose is 400 mg, taken orally once daily until disease progression or intolerable toxicity occurs.\u003c\/p\u003e\u003cp\u003eIt is recommended to take this product immediately after a meal at the same time every day.\u003c\/p\u003e\u003ch3\u003eDose adjustment\u003c\/h3\u003e\u003cp\u003eDoctors should closely monitor patients during medication and adjust medication according to individual patient safety and tolerability, including suspending this product, reducing the dose, or permanently discontinuing this product.\u003c\/p\u003e","brand":"HUTCHMED, China","offers":[{"title":"Default Title","offer_id":44797953835051,"sku":"RL2320241030","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-10-291.jpg?v=1787022211","url":"https:\/\/xomeds.com\/products\/orpathys-savolitinib","provider":"XOMEDS","version":"1.0","type":"link"}